Advertisement
Screener

Neurogene Inc. (NGNE) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements

2.5 / 5 stars · 25/51 Roast Me

Neurogene Inc. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements

Neurogene Inc. (NGNE) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.

Financial Statements › Notes › Earnings Per Share

us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2025-03-24

  • Neurogene Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2018-06-30 was 324.54K shares.
  • Neurogene Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2024 was 0.00 shares.
Period endIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 0 monthIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 monthIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month
2024-12-310.00 shares
10-K · filed 2025-03-24
2023-12-31101.72K shares
10-K · filed 2025-03-24
2018-06-30324.54K shares
10-Q · filed 2019-08-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76